MAY 13, 2020 8:18 AM PDT

FDA Fast Tracks Vaccine for COVID-19

WRITTEN BY: Annie Lennon

Biopharmaceutical company, Moderna, has announced that the US Food and Drug Administration has approved its experimental COVID-19 vaccine for a Phase II trial. 

The vaccine, known as mRNA-1273, was developed by both Moderna and the National Institutes of Health. It was the first candidate to enter a Phase I human trial in March. Although the results of this trial remain unpublished, the FDA granted them federal approval to continue their research via Phase II trial soon. Meanwhile, the company hopes to begin phase III trials, the final trialing phase, early this summer. 

One of the reasons for the vaccine’s swift approval is that it operates via a system used to make other vaccines that has shown to be both effective and without huge risk to patients’ health. Rather than using an inactive form of COVID-19, this method instead introduces patients to synthetic RNA molecules in the hope that their body will recognize them as the virus and produce antibodies that may also fight against the real thing. 

In the vaccine’s Phase II trial, the researchers aim to assess the safety, reactogenicity and immunogenicity of two vaccinations given 28 days apart. They hope to recruit 600 healthy volunteers aged 18 and over, and will then follow each of them for 12 months after the second vaccination. 

Should the vaccine pass the Phase II trial, Moderna anticipates working closely with the US government to decide where its first doses will be delivered. To this end, the company has already begun scaling up its manufacturing capacity to rapidly distribute the vaccine once available. 

Optimistic, the company’s CEO Stephane Bancel nevertheless said that even if approved, supply of the vaccine will remain constrained for some time. Due to the number of cases of the virus globally, he added that soon, there will likely be more than one vaccine in circulation to fight the virus. 

 

Sources: CNBC, LabRoots, Clinical Trials Arena

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 23, 2022
Drug Discovery & Development
No Evidence for Depression and Serotonin Activity Link
JUL 23, 2022
No Evidence for Depression and Serotonin Activity Link
A new review study found that there is no clear evidence that serotonin levels or serotonin activity are responsible for ...
AUG 07, 2022
Drug Discovery & Development
Monoclonal Antibody Treatment Shows Promise in Preventing Malaria
AUG 07, 2022
Monoclonal Antibody Treatment Shows Promise in Preventing Malaria
A singular injection of a monoclonal antibody treatment candidate has been shown as safe and highly protective in US adu ...
AUG 16, 2022
Neuroscience
Phone Therapy Shows Promise for Treating Tinnitus
AUG 16, 2022
Phone Therapy Shows Promise for Treating Tinnitus
 A phone-based therapy has shown encouraging results in treating tinnitus in a recent clinical trial. The correspon ...
AUG 27, 2022
Drug Discovery & Development
Universal Vaccine for Influenza A and B Shows Promise in Mice
AUG 27, 2022
Universal Vaccine for Influenza A and B Shows Promise in Mice
A new universal flu vaccine is effective against both influenza A and B viruses in mice. The corresponding study was pub ...
SEP 16, 2022
Drug Discovery & Development
A magic cure for alcohol use disorder: FDA approves synthetic psilocybin as an investigational new drug for alcohol use disorder.
SEP 16, 2022
A magic cure for alcohol use disorder: FDA approves synthetic psilocybin as an investigational new drug for alcohol use disorder.
Are mushrooms the magic therapeutic to help overcome alcohol use disorder? New data published last month suggest that th ...
SEP 26, 2022
Drug Discovery & Development
Respiratory Syncytial Virus Antigens and Antibodies
SEP 26, 2022
Respiratory Syncytial Virus Antigens and Antibodies
In early April, Pfizer announced a $525 million acquisition of ReViral’s novel therapy for respiratory syncytial v ...
Loading Comments...